anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Devices and methods for providing medical treatment sessions to a subject are disclosed. The treatment sessions may comprise one or more parameters controllable by the subject in real time and one or more parameters that are remotely controllable in real time. The treatment session may be displayed at the patient's device. A user control module may alter said one or more controllable parameters by the user. A communication module may be configured to transmit, in real time, the treatment session and information related to the controllable parameters to a remote device and receive instructions, in real time, from the remote device to alter said one or more remotely controllable parameters. A treatment control module may be configured to alter said one or more remotely controllable parameters during the treatment session in response to the received instructions.
Despite that surgical resection is widely regarded as the most effective approach to the treatment of liver cancer, its safety and efficacy upon centrally located hepatocellular carcinoma (HCC) remain unsatisfactory. In consequence, seeking an integrated treatment, like combined with adjuvant radiotherapy, to enhance the prognosis of patients is of critical importance. By recruiting patients undergoing surgical resection for centrally located HCC ranging from June 2015 to 2020, they were divided into liver resection combined with adjuvant radiotherapy (LR + RT) and mere liver resection (LR) groups. The calculation of propensity score and model of Cox proportional hazards regression were utilized. 193 patients were recruited in aggregation, containing 88 ones undergoing LR + RT, while 105 handled with LR. RT was verified to be an independent factor of prognosis for relapse (HR 0.60). In propensity-score analyses, significant association existed between adjuvant radiotherapy and better disease-free survival (DFS) (Matched, HR 0.60; Adjustment of propensity score, HR 0.60; Inverse probability weighting, HR 0.63). The difference of DFS was apparent within two groups (p value = 0.022), and RT significantly down-regulated early relapse (p value < 0.05) in subgroup analysis. The calculation of E-value revealed robustness of unmeasured confounding. The combination of liver surgical resection with RT is safe and effective towards patients with centrally located HCC, which would notably enhance the prognosis and decrease the early relapse of HCC.
Many spine surgeons are not optimally acquainted with anatomy anterior to sacrum. Screw malposition injuring these structures can lead to unwanted lethal consequences. We report unusual cases of acute radiculopathy due to misplaced bicortical sacral screw causing L5 nerve root impingement on anterior sacrum. A 39/M patient complained of severe rest pain (VAS 9/10) post TLIF in region of L5 dermatome with sensory deficit along the right lateral leg and straight leg raise less than 30°. X-ray revealed S1 screw protruding beyond the second cortex with a straight trajectory. CT scan revealed a protrusion of 11.4mm beyond anterior cortex. The patient was taken for re-surgery and the trajectory and length of screw was revised. Sciatic pain completely disappeared immediately after surgery. A 61/M patient operated elsewhere with instrumented decompression and fusion with screws passed at L4, L5 and S1 level for lumbar canal stenosis, post-surgery patient developed new onset radicular symptoms in right lower limb. Patient was managed conservatively in the form of L5 selective nerve root block. Pain and numbness improved. Bicortical purchase of S1 screw though improves pull out strength, is associated with a risk of neurovascular complications. Surgeons should be alerted to the misplacement of S1 pedicle screws to avoid involvement not only anterior to the anteromedial neurovascular tissue, but also anterolateral to the arrangement of the L5 nerve root.
PURPOSE:To obtain the title pharmaceutical preparation each containing thrombin as hemostatic ingredient, gelatin, etc., as a stabilizer and white sugar, etc., as a vehicle, being stable for a long period at ambient temperature, having excellent solubility and usable as a form of powder, fine grain, granule, etc., and suitable for treatment of bleeding from upper digestive tract. CONSTITUTION:In the title pharmaceutical preparation, a stabilizer (e.g. gelatin, albumin or glycine) of 10-50mg and a vehicle (e.g. white sugar, lactose or D- mannitol) of 0.5-1g per 10000 unit thrombin are blended. The above-mentioned preparation is used by dissolving the preparation in to buffer, cow milk, physiological saline, distilled water, etc., and controlling the concentration of thrombin to 50-100unit/ml. The preparation is dissolved within 1 min in a solvent and the solution is free from precipitation. Further, thrombin activity in the solution is not lowered for 24hr.
This study is planned as a randomized control trial. Patients will be randomly divided into two groups a clinical group and a home group. The clinical group will be received LSVT-BIG training four times a week for four weeks in the clinic. The home group will be received LSVT-BIG training two times a week for four weeks at the home and two times a week for four weeks at the clinical.

All assessments will be done before and after the 4-week intervention program or waiting period. The demographic characteristics of the participants initially will be taken. The outcome measures are balance and gait assessments.
Accurate postoperative assessment is critical for optimizing 131I therapy in patients with papillary thyroid cancer (PTC). This study aimed to develop a pathology model utilizing postoperative digital pathology slides to predict lymph node and/or distant metastases on post-therapeutic 131I scan after initial 131I treatment in PTC patients. A retrospective analysis was conducted on 229 PTC patients who underwent total or near-total thyroidectomy and subsequent 131I treatment after levothyroxine (LT4) withdrawal between January 2022 and August 2023. The pathology model was developed through two stages: patch-level prediction and WSI-level prediction. The clinical model was constructed using statistically significant variables identified from univariate and multivariate logistic regression analysis. Of the 229 patients, 19.6% (45/229) exhibited 131I-avid metastatic foci in post-therapeutic 131I scan. Multifactorial analysis identified stimulated thyroglobulin (sTg) as the sole independent risk factor. The AUC of the pathology model in the training and test cohorts were 0.976 (95% CI 0.948-1.000) and 0.805 (95% CI 0.660-0.951), respectively, which were significantly higher than the clinical model (AUC 0.652 and 0.548, Pall < 0.05). This model has the potential to serve as a valuable tool for clinicians in tailoring treatment strategies, thereby optimizing therapeutic outcomes for PTC patients.
Emphysema affects an estimated 60 million people worldwide and is a major cause of morbidity and mortality. In its most basic terms, emphysema causes the destruction of lung parenchyma resulting in collateral ventilation from one part of the lung to another through the disrupted alveolar walls, to the point that gas transport from one part of the lung to another may exceed gas flow through the small airways. In other words, the gas can move freely about within the lung, but it cannot get out, which causes over inflation, or hyperinflation of the diseased lung. When the disease is far advanced, patients are afflicted with disabling dyspnea that progressively restricts their activities and eventually causes great suffering. The crippling effects of end-stage emphysema, including severe dyspnea and marked limitation of activities, relate in large measure to the dynamic hyperinflation of the lungs associated with the loss of elasticity, gas trapping and collapse of small airways. The progressive enlargement of the thorax and flattening of the diaphragm render inspiratory muscles inefficient, increase the work of breathing and contribute to a feeling of breathlessness. The major medical therapeutic modalities include bronchodilator and anti-inflammatory drugs directed at decreasing airway resistance and antibiotics to combat infection. Pulmonary rehabilitation techniques and exercise training have proven of palliative benefit. In general, the results of medical treatment for advanced airway obstruction frequently result in a persistently anguished patient and frustrated physician. A system that could efficiently decompress emphysematous lungs with each breath would result in significant clinical benefit, including lessened dyspnea, decreased work of breathing, and increased exercise tolerance.

In addition to medical therapies, there are two surgical therapies available to emphysema sufferers: Lung transplantation and Lung Volume Reduction Surgery (LVRS). In the National Emphysema Treatment Trial (NETT), LVRS was shown to be effective in a sub-set of emphysema patients, but it had the drawback of increased short-term mortality as compared to the medical control arm. This was likely due to the invasiveness of LVRS.

Lung transplantation is a widely accepted surgical treatment for emphysema; however it is an unrealistic option for most patients. The selection criteria are very stringent for acceptance to receive a donor lung(s). Lung transplantation carries a high long-term morbidity and mortality and is severely limited by the shortage of available donor lungs.

We seek to take advantage of collateral ventilation seen in advanced emphysema by creating passageways from the lung parenchyma to large airways, through which air can escape the lungs during exhalation. The Exhale therapeutic intervention should be applicable to the majority of emphysema patients who suffer from hyperinflation of their lungs. It would be desirable to have a therapeutic option that is both less invasive and more readily available to emphysema sufferers. We have been working on such a therapy and have begun to investigate it in the clinic.
The invention provides a traditional Chinese medicine composition with homology of medicine and food, a preparation method and application thereof, belonging to the technical field of functional foods. The traditional Chinese medicine composition comprises the following components: codonopsis pilosula, ginseng, rhizoma polygonati, dark plum, honey-fried licorice root, honey-fried astragalus root, Chinese angelica, Chinese date, medlar, dried orange peel, cinnamon, poria cocos, Chinese yam, clove, spina date seed, lotus seed, malt, longan aril, lotus leaf, black sesame and pawpaw. The traditional Chinese medicines selected by the invention are medicinal and edible medicinal materials, have high safety and no toxic or side effect, and have the effects of tonifying qi and warming yang. The health-care tea is further prepared into a traditional Chinese medicine beverage, and can be used for relieving various weakness manifestations caused by fatigue and weakness, sleep disorder, easy cold intolerance, cold hands and feet, age-incompatible physiological function reduction, improving immunity and preventing respiratory tract infection. Also can be used for athlete training to enhance endurance. Therefore, it has good practical application value.
Composition comprises at least one chlorite and a polyvalent alcohol in aqueous or alcoholic-aqueous chlorine dioxide-containing solution without other chlorine oxide compounds, chlorates and oxidants, preferably peroxides. The composition has a pH value of >= 4. Independent claims are also included for: (1) a solid material composition for preparing the composition by dissolving the solid material composition in water and/or alcohol; and (2) an agent for internal or external application for therapeutic, prophylactic, cosmetic or health-promoting functions in humans and animals, comprising the composition or the solid material composition. ACTIVITY : Antibacterial. No biological data given. MECHANISM OF ACTION : None given.
The invention relates to a medicine composition used for treating common cold, wind cold, and lung and stomach heat stagnation. The medicine composition has the advantages of superficies relieving, cold relieving, heat clearing, lung ventilating, detoxifying, and sore-throat relieving. The medicine composition comprises main components of Chinese thorowax root, lobed kudzuvine root, Baikal skullcap root, blackberry lily, gypsum, mix-fried Chinese ephedra herb, beef-steak plant leaf, incised notopterygium rhizome and root, giant knotweed rhizome, biod magnolia flower bud, and raw licorice root, which are plants which can be adopted in both medicines and medicated diets. The medicine composition has main functions of superficies relieving, cold relieving, heat clearing, lung ventilating, detoxifying, and sore-throat relieving. The medicine composition is used in wind cold and various lung and stomach heat stagnation syndromes, and can be applied on external-cold-and-internal-heat syndromes such as influenza, common cold, acute bronchitis, early-stage pneumonia, and the like. The syndromes comprise: fever, chill and no sweat or poor sweat vent, headache, whole-body sores and pains, nasal congestion, runny nose, sore throat or itchy and dry throat, cough, blocked phlegm, red tongue yellow or white, and floating pulse. The medicine composition can be prepared into tablets, capsules, granules, pills, oral liquid preparations, and the like.
BACKGROUND: Particulate β-glucans (WGP) are natural compounds with regulatory roles in various biological processes, including tumorigenesis and inflammatory diseases such as allergic asthma. However, their impact on mast cells (MCs), contributors to airway hyperresponsiveness (AHR) and inflammation in asthma mice, remains unknown.
METHODS: C57BL/6 mice underwent repeated OVA sensitization without alum, followed by Ovalbumin (OVA) challenge. Mice received daily oral administration of WGP (OAW) at doses of 50 or 150 mg/kg before sensitization and challenge. We assessed airway function, lung histopathology, and pulmonary inflammatory cell composition in the airways, as well as proinflammatory cytokines and chemokines in the bronchoalveolar lavage fluid (BALF).
RESULTS: The 150 mg/kg OAW treatment mitigated OVA-induced AHR and airway inflammation, evidenced by reduced airway reactivity to aerosolized methacholine (Mch), diminished inflammatory cell infiltration, and goblet cell hyperplasia in lung tissues. Additionally, OAW hindered the recruitment of inflammatory cells, including MCs and eosinophils, in lung tissues and BALF. OAW treatment attenuated proinflammatory tumor necrosis factor (TNF)-α and IL-6 levels in BALF. Notably, OAW significantly downregulated the expression of chemokines CCL3, CCL5, CCL20, CCL22, CXCL9, and CXCL10 in BALF.
CONCLUSION: These results highlight OAW's robust anti-inflammatory properties, suggesting potential benefits in treating MC-dependent AHR and allergic inflammation by influencing inflammatory cell infiltration and regulating proinflammatory cytokines and chemokines in the airways.
At pre-treatment Visit 3, imaging data will be acquired to generate a patient-specific bronchial thermoplasty treatment plan which will include 15-20 target airways, prioritized in order of importance and grouped by lobe, to be targeted during a single session BT treatment procedure. Airways demonstrating dynamic or static bronchoconstriction will be targeted for BT treatment based on their spacial proximity to ventilation defects.
Risk Summary

Based on findings from animal studies and its mechanism of action, pemetrexed for injection can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1)]. There are no available data on pemetrexed for injection use in pregnant women. In animal reproduction studies, intravenous administration of pemetrexed to pregnant mice during the period of organogenesis was teratogenic, resulting in developmental delays and malformations at doses lower than the recommended human dose of 500 mg/m2 [see Data]. Advise pregnant women of the potential risk to a fetus [see Use in Special Populations (8.3)]. 

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. 

Data

Animal DataPemetrexed was teratogenic in mice. Daily dosing of pemetrexed by intravenous injection to pregnant mice during the period of organogenesis increased the incidence of fetal malformations (cleft palate; protruding tongue; enlarged or misshaped kidney; and fused lumbar vertebra) at doses (based on BSA) 0.03 times the human dose of 500 mg/m2. At doses, based on BSA, greater than or equal to 0.0012 times the 500 mg/m2 human dose, pemetrexed administration resulted in dose-dependent increases in developmental delays (incomplete ossification of talus and skull bone; and decreased fetal weight).
The proposed investigation is a randomized, double-blind, placebo and positive-controlled clinical study to evaluate the role of the cytokine tumor necrosis factor alpha (TNF-alpha) modulator, thalidomide, in acute inflammation and analgesia. The analgesic effect of thalidomide, a putative TNF-alpha modulator, will be evaluated using a model of tissue injury, the oral surgery model. Briefly, healthy males referred for third molar extraction will undergo the surgical extraction of third molars using standard surgical methods. At the completion of the surgical procedure, a microdialysis probe will be placed under the mucogingival flap previously elevated for the surgical procedure and subjects will be observed for pain over the course of six hours following surgery. Thalidomide or control will be administered one hour prior to surgery. Tissue levels of pro-inflammatory cytokines, and inflammatory mediators will be measured at time intervals postoperatively concomitant with pain measurements. Pain will be assessed postoperatively over the course of six hours. Demonstration of amelioration of pain is the primary outcome measure; changes in levels of tissue mediators will be taken as evidence of an acute anti-inflammatory effect of thalidomide. Based on our previous work with the fusion protein etanercept (TNFR:fc) which specifically binds TNF-alpha and prevents its interaction with cellular receptors, similar changes in the inflammatory cascade and clinical endpoints of inflammation may provide insight into the activity of thalidomide on acute inflammation and its clinical sequela, pain.
FIELD: medicine, virology, vaccines. SUBSTANCE: invention relates to preparing living an antiinfluenza living vaccine for adults and children corresponding to an actual virus A/Nanchang/933/ 95 (H3N2) by antigenic properties. Vaccine strain A/17/ Nanchang/95/4 (H3N2) is a reassortant obtained by breeding an epidemic virus A/Nanchang/933/95 (H3N2) with cold-adapted temperature-sensitive virus A/Leningrad/134/17/57 (H2N2) as an attenuation donor. Strain is harmless for adults, its properties provide preparing reassortant vaccine strains from newly appearing epidemic viruses. Strain A/17/Nanchang/95/4 (H3N2) multiplicates actively in developing chicken embryos at optimal temperature 34 C, it shows temperature-sensitivity and cold-adaptation. Strain inherited two genes encoding surface proteins (hemagglutinin and neuraminidase) from epidemic virus and six genes encoding nonglycosylated proteins from attenuation donor. Strain A/17/Nanchang/95/4 (H3N2) is nonreactive for adults at intranasal administration and corresponds to immunogenicity indices. Vaccine strain A/17/Nanchang/95/4 (H3N2) by biological properties and nonreactivity indices corresponds to requirements for vaccine strains by Pharmacopoeia article FS 42-299 VS-89 for living antiinfluenza vaccine for intranasal use for adults. EFFECT: strain indicated above. 1 tbl, 1 ex
A single intra-canal substance composition for tissue dissolution, disinfection, tissue degradation, tissue removal and disinfection is provided. The composition includes calcium hydroxide, sodium hydroxide, potassium thioglycolate or calcium thioglycolate, to form an effective single intra-canal substance capable of degrading a cell by disrupting its disulfide bonds. Further, the composition may incorporate mineral oil, urea, cetearyl alcohol, D&C yellow No. 8, chromium hydroxide, theobroma cocoa seed butter, iron oxides, fragrances, water fragrance, lanolin, and ceteareth-20 to enhance its functioning. Furthermore, the composition that is bactericidal against  Enterococcus faecalis, Streptococcus mutans  and  Candida albicans , used in multiple applications in dentistry and medicine. Furthermore, the composition is a single intra-canal irrigant that eradicates microorganisms as it facilitates the chemo-mechanical debridement of the root canal system.
The invention provides an application of a small molecular compound YZL-51N in preparing SIRT7 selective inhibitor. The invention discovers that a small molecular compound YZL-51N can be used as a specific small molecular inhibitor of SIRT 7. The invention utilizes the polypeptide deacetylation to verify that the compound YZL-51N can effectively inhibit the activity of SIRT7 deacetylase. Compared with other sirtuins family members, the invention also proves that YZL-51N has stronger interaction affinity with SIRT7 through a BLI experiment method. The invention confirms that the small molecular compound is inserted into the pocket and interacted with the hot spot amino acid through a molecular docking experiment. In the cell model, YZL-51N can also specifically inhibit SIRT7 and supplement its substrate. The compound can effectively inhibit SIRT7-ATM cell signal path under the stimulation of ion radiation.
Thrombolysis with intravenous(iv) tissue plasminogen activator (t-PA) is the only effective and approved therapy for acute ischemic stroke. The most frequent cause of ischemic stroke is thrombosis of the middle cerebral artery (MCA). Preliminary in vitro, animal and human studies suggest that ultrasound accelerates thrombolysis induced by t-PA, and recanalization of acute MCA occlusion due to thrombolysis is an independent predictor of good clinical outcome. Thus, insonation of an occluded MCA through the temporal bone in stroke patients who are treated with iv t-PA might enhance recanalization and improve clinical outcome. The present prospective, randomized, controlled multicenter pilot study will investigate the safety and efficacy of continuous 1-hour insonation of the occluded MCA with 2 MHz transcranial color duplex sonography in patients with ischemic stroke treated with iv t-PA within 3 hours after symptom onset. It is planned to randomize 400 patients in 6 Swiss centers during an enrolment period of 33 months with an individual follow up of 3 months. The study endpoints include safety and efficacy assessments. The primary safety endpoint is to determine the rate of symptomatic intracranial hemorrhage (ICH) in both treatment groups. The primary efficacy endpoint is to determine whether a good functional outcome (modified Rankin scale, mRs, score of 0-2) differs between both treatment groups. Secondary endpoints include (1) asymptomatic ICH occuring during or within the first 24-48 hours after t-PA infusion, (2) early clinical recovery by 10 or more National Institute of Health Stroke Scale (NIHSS) points or dramatic recovery (total NIHSS score of 3 or less) at 24-48 hours after t-PA infusion, (3) mean mRS score at 90 days after t-PA infusion, (4) death occuring during the study period, and (5) recanalization at 24-48 hours after t-PA infusion.
These patients were video taped before they had any inhaler education using their own inhalers. They were then given online video education located at use-inhalers.com, and were asked to complete the education (took on average 5 minutes). They were then re-taped for their inhaler technique.